Medtronic’s PFA-led growth acceleration and planned MiniMed separation could unlock margins and valuation, supporting a 10.7% base-case annualized five-year return despite execution and leverage risks.
Overview
Medtronic is the largest public pure-play medical-equipment company, serving more than 82 million patients annually across 70 conditions and operating in over 150 countries. FY26 revenue was $36.364 billion, diversified across Cardiovascular at $13.976 billion, Neuroscience at $10.287 billion, Medical Surgical at $8.815 billion, and Diabetes at $3.112 billion; geography was nearly balanced between the United States and international markets. **The operating trajectory has accelerated:** Q1 FY27 revenue rose 13.7% to $9.756 billion, or approximately 7.4% excluding the estimated $570 million benefit from a 53rd selling week. Non-GAAP EPS was $1.45 versus $1.39 consensus, gross margin was 65.2%, operating margin was 23.7%, and free cash flow more than doubled to $1.290 billion. Management raised FY27 organic growth guidance to 7.25%-7.75% and EPS guidance to $5.94-$6.00. The central valuation catalyst is the planned MiniMed separation, which should improve mix and margins, alongside PFA, AiBLE, Hugo, and renal-denervation growth. Against a $91 baseline, the base case implies $135.66 in five years and a 10.7% annualized return.